Investigational drug · Phase 2
E7386
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "E7386"
First trial start
2019
Jul 11, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "E7386", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Neoplasms
- Neoplasms
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Colorectal Neoplasms
Approved drugs for the same conditions: Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "E7386" as an intervention, largest first.
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorPivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT04008797 · 301 participants (planned) · Start Jul 11, 2019 · Primary completion Mar 31, 2027
Drug: E7386; Lenvatinib and 2 more · For: Endometrial Neoplasms; Neoplasms; Carcinoma, Hepatocellular and 2 more
Sites: Little Rock, Arkansas; La Jolla, California; Los Angeles, California · 106 sites in all
Eisai Inc.Eisai
NCT05091346 · 89 participants · Start Oct 27, 2021 · Primary completion Oct 15, 2024
Drug: E7386; Pembrolizumab and 1 more · For: Melanoma; Carcinoma, Hepatocellular; Colorectal Neoplasms
Sites: Los Angeles, California; Orange, California; Fort Myers, Florida · 32 sites in all
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruiting
Eisai Co., Ltd.Eisai
NCT03833700 · 70 participants (planned) · Start Mar 5, 2019 · Primary completion Mar 31, 2027
Drug: E7386 · For: Solid Neoplasms; Colorectal Neoplasms; Gastrointestinal Tumors
Sites: Nagoya, Japan; Kashiwa, Japan; Sapporo, Japan · 8 sites in all
- Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruiting
Eisai Inc.Eisai
NCT03264664 · 60 participants (planned) · Start Jul 27, 2017 · Primary completion Mar 31, 2027
Drug: E7386 · For: Advanced Neoplasms
Sites: Phoenix, Arizona; Los Angeles, California; Pasadena, California · 10 sites in all
Eisai Inc.Eisai
NCT03996226 · 17 participants · Start Jun 7, 2019 · Primary completion Oct 29, 2019
Drug: E7386 · For: Food Effect in Healthy Participants
Sites: Austin, Texas
Eisai LimitedEisai
NCT05607537 · 15 participants · Start Oct 17, 2022 · Primary completion Aug 31, 2023
Drug: E7386 Tablet; (14C)E7386 Capsule and 1 more · For: Healthy Volunteers
Sites: Leeds, United Kingdom
Eisai LimitedEisai
NCT04840927 · 0 participants · Start Apr 9, 2021 · Primary completion May 17, 2023
Drug: E7386 · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort.
Lee JY, Hasegawa K, Kim BG, et al. · EClinicalMedicine 2026
- A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.
Evans TRJ, Cook N, El-Khoueiry A, et al. · Br J Cancer 2026
- A Phase 1 Oral Mass Balance and Combined Intravenous [14C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans.
Pathak SM, Hayata N, Ueno T, et al. · J Clin Pharmacol 2026
- E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.
Kondo S, Yamamoto N, Katsuya Y, et al. · ESMO Open 2025
- E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.
Mesropian A, Gris-Oliver A, Balaseviciute U, et al. · Clin Cancer Res 2025
- Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Eskander RN, Lee JY, Mirza MR, et al. · Int J Gynecol Cancer 2025
Also in development for Endometrial Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.